Follow-up of Gambian children recruited to a pilot safety and immunogenicity study of the malaria vaccine SPf66

Kalifa A. Bojang, Stephen K. Obaro, Amanda Leach, Umberto D'Alessandro, Stephen Bennett, Wolfram Metzger, W. Ripley Ballou, Geoffrey A.T. Targett, Brian M. Greenwood

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A pilot safety and immunogenicity trial of the malaria vaccine SPf66 was undertaken in The Gambia in 1993. One hundred and fifty infants aged 6-11 months were immunized with either 0.5 mg or 1.0 mg of SPf66 produced either in Colombia or in the USA or with a control vaccine. Children who received SPf66 experienced more clinical attacks of malaria than did children in the control group during the first period of surveillance and the difference in incidence between children who had received high dose Colombian vaccine and the control children was statistically significant at the 5% level. During the 1995 malaria transmission season, 127 children from the original cohort of 150 were observed. During 18 weeks of intensive surveillance, the incidence of clinical malaria was again higher among children who had received SPf66 than among children who had received inactivated polio vaccine (6.23 vs 4.89 clinical attacks per 1000 days at risk), the effect being most marked among children who were in the high dose groups, but differences between groups were now no longer statistically significant.

Original languageEnglish (US)
Pages (from-to)579-581
Number of pages3
JournalParasite Immunology
Volume19
Issue number12
DOIs
StatePublished - Jan 1 1997

Fingerprint

Malaria Vaccines
Safety
Malaria
Vaccines
Gambia
Inactivated Vaccines
Colombia
Incidence
Poliomyelitis
Control Groups

Keywords

  • Gambian children
  • Malaria
  • SPf66
  • Vaccine

ASJC Scopus subject areas

  • Parasitology
  • Immunology

Cite this

Follow-up of Gambian children recruited to a pilot safety and immunogenicity study of the malaria vaccine SPf66. / Bojang, Kalifa A.; Obaro, Stephen K.; Leach, Amanda; D'Alessandro, Umberto; Bennett, Stephen; Metzger, Wolfram; Ripley Ballou, W.; Targett, Geoffrey A.T.; Greenwood, Brian M.

In: Parasite Immunology, Vol. 19, No. 12, 01.01.1997, p. 579-581.

Research output: Contribution to journalArticle

Bojang, KA, Obaro, SK, Leach, A, D'Alessandro, U, Bennett, S, Metzger, W, Ripley Ballou, W, Targett, GAT & Greenwood, BM 1997, 'Follow-up of Gambian children recruited to a pilot safety and immunogenicity study of the malaria vaccine SPf66', Parasite Immunology, vol. 19, no. 12, pp. 579-581. https://doi.org/10.1046/j.1365-3024.1997.d01-171.x
Bojang, Kalifa A. ; Obaro, Stephen K. ; Leach, Amanda ; D'Alessandro, Umberto ; Bennett, Stephen ; Metzger, Wolfram ; Ripley Ballou, W. ; Targett, Geoffrey A.T. ; Greenwood, Brian M. / Follow-up of Gambian children recruited to a pilot safety and immunogenicity study of the malaria vaccine SPf66. In: Parasite Immunology. 1997 ; Vol. 19, No. 12. pp. 579-581.
@article{cff93e36a7cb4d59a5c078fef922b663,
title = "Follow-up of Gambian children recruited to a pilot safety and immunogenicity study of the malaria vaccine SPf66",
abstract = "A pilot safety and immunogenicity trial of the malaria vaccine SPf66 was undertaken in The Gambia in 1993. One hundred and fifty infants aged 6-11 months were immunized with either 0.5 mg or 1.0 mg of SPf66 produced either in Colombia or in the USA or with a control vaccine. Children who received SPf66 experienced more clinical attacks of malaria than did children in the control group during the first period of surveillance and the difference in incidence between children who had received high dose Colombian vaccine and the control children was statistically significant at the 5{\%} level. During the 1995 malaria transmission season, 127 children from the original cohort of 150 were observed. During 18 weeks of intensive surveillance, the incidence of clinical malaria was again higher among children who had received SPf66 than among children who had received inactivated polio vaccine (6.23 vs 4.89 clinical attacks per 1000 days at risk), the effect being most marked among children who were in the high dose groups, but differences between groups were now no longer statistically significant.",
keywords = "Gambian children, Malaria, SPf66, Vaccine",
author = "Bojang, {Kalifa A.} and Obaro, {Stephen K.} and Amanda Leach and Umberto D'Alessandro and Stephen Bennett and Wolfram Metzger and {Ripley Ballou}, W. and Targett, {Geoffrey A.T.} and Greenwood, {Brian M.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1046/j.1365-3024.1997.d01-171.x",
language = "English (US)",
volume = "19",
pages = "579--581",
journal = "Parasite Immunology",
issn = "0141-9838",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Follow-up of Gambian children recruited to a pilot safety and immunogenicity study of the malaria vaccine SPf66

AU - Bojang, Kalifa A.

AU - Obaro, Stephen K.

AU - Leach, Amanda

AU - D'Alessandro, Umberto

AU - Bennett, Stephen

AU - Metzger, Wolfram

AU - Ripley Ballou, W.

AU - Targett, Geoffrey A.T.

AU - Greenwood, Brian M.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - A pilot safety and immunogenicity trial of the malaria vaccine SPf66 was undertaken in The Gambia in 1993. One hundred and fifty infants aged 6-11 months were immunized with either 0.5 mg or 1.0 mg of SPf66 produced either in Colombia or in the USA or with a control vaccine. Children who received SPf66 experienced more clinical attacks of malaria than did children in the control group during the first period of surveillance and the difference in incidence between children who had received high dose Colombian vaccine and the control children was statistically significant at the 5% level. During the 1995 malaria transmission season, 127 children from the original cohort of 150 were observed. During 18 weeks of intensive surveillance, the incidence of clinical malaria was again higher among children who had received SPf66 than among children who had received inactivated polio vaccine (6.23 vs 4.89 clinical attacks per 1000 days at risk), the effect being most marked among children who were in the high dose groups, but differences between groups were now no longer statistically significant.

AB - A pilot safety and immunogenicity trial of the malaria vaccine SPf66 was undertaken in The Gambia in 1993. One hundred and fifty infants aged 6-11 months were immunized with either 0.5 mg or 1.0 mg of SPf66 produced either in Colombia or in the USA or with a control vaccine. Children who received SPf66 experienced more clinical attacks of malaria than did children in the control group during the first period of surveillance and the difference in incidence between children who had received high dose Colombian vaccine and the control children was statistically significant at the 5% level. During the 1995 malaria transmission season, 127 children from the original cohort of 150 were observed. During 18 weeks of intensive surveillance, the incidence of clinical malaria was again higher among children who had received SPf66 than among children who had received inactivated polio vaccine (6.23 vs 4.89 clinical attacks per 1000 days at risk), the effect being most marked among children who were in the high dose groups, but differences between groups were now no longer statistically significant.

KW - Gambian children

KW - Malaria

KW - SPf66

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=0031465892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031465892&partnerID=8YFLogxK

U2 - 10.1046/j.1365-3024.1997.d01-171.x

DO - 10.1046/j.1365-3024.1997.d01-171.x

M3 - Article

C2 - 9458470

AN - SCOPUS:0031465892

VL - 19

SP - 579

EP - 581

JO - Parasite Immunology

JF - Parasite Immunology

SN - 0141-9838

IS - 12

ER -